York firm's subsidiary signs distribution agreement for four new territories

York-based Optibiotix said its ProBiotix Health subsidiaryhas entered into a non-exclusive distribution agreement with Actial Farmaceutica Srl for the distribution of CholBiome and CholBiomeX3 in four new territories in the Asia Pacific region.

Actial is an Italian holding company with three subsidiaries worldwide: CD Pharma India, Actial APAC and VSL Pharmaceuticals focused on the development of probiotic bacteria to improve gut health.

It is the developer and originator of one of the world's best known probiotic brands called VSL#3.

The agreement grants Actial the right to distribute ProBiotix's cholesterol and blood pressure reducing dietary supplements, CholBiome® and CholBiomeX3 in Australia, New Zealand, Indonesia and Thailand.

CholBiome and CholBiomeX3 will be marketed under the VSL#3 range to hospital clinicians, GPs and pharmacies as probiotic dietary food supplements for the management of high cholesterol and blood pressure.

ProBiotix was created to develop science based healthy lactic acid bacteria called probiotics to reduce cardiovascular risk.

Since launching its CholBiome products containing LP LDL in May 2017, ProBiotix has signed approximately 30 agreements with products commercialised in 50 countries.

Mikkel Hvid-Hansen, commercial director of ProBiotix Health, said: "We are pleased to announce the signing of this distribution agreement with ActialFarmaceutica Srl as we believe cholesterol reducing probiotics likeLPLDL are increasingly being seen by clinicians and health care professionals as a naturally safe and effective approach to reducing cardiovascular risk.

"We chose Actial due to a common interest in developing probiotics with strong science and clinical studies and their expertise in commercialising value added probiotics to major global pharmaceutical markets.

"We believe working with Actial, and similar partners around the world, provides the best opportunity to expand the range of applications for LP LDL and CholBiome to a wide range of industry sectors.

"This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors."